title: Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
abstract: BACKGROUND
  Chromosome 1p deletions are common in advanced neuroblastomas, but the biological and clinical implications of this clonal rearrangement remain controversial. Previous studies of chromosome 1p loss of heterozygosity (LOH) have been limited by analyses of relatively small number of tumors derived from heterogeneously assessed and treated patient populations. Therefore, a strictly representative cohort of 288 Children's Cancer Group neuroblastoma patients treated on the most recent phase III therapeutic trials was identified.
  
  
  METHODS
  Primary tumors from these patients were analyzed for LOH at precisely mapped and highly informative 1p polymorphic loci located from 1p32 to 1p36.3 by multiplex PCR.
  
  
  RESULTS
  Ninety-three primary tumor specimens (32%) had LOH at multiple 1p36 marker loci. All 1p deletions overlapped the previously determined smallest region of overlap (SRO). One tumor had a small terminal deletion completely within 1p36.3, allowing for further refinement of the 1p36 SRO. We found no evidence to support an additional, nonoverlapping region of LOH within 1p32-36. We confirmed the strong correlation of 1p36 LOH with MYCN amplification (P < 0.001), advanced disease stage (P < 0.001), and decreased both 3-year event-free survival and overall survival probabilities (P< 0.001). When stratified for MYCN amplification status or entered into a multivariate analysis, 1p36 LOH remained predictive for decreased event-free survival, but not overall survival probability.
  
  
  CONCLUSIONS
  These data support the hypothesis that inactivation of a tumor suppressor gene within 1p36.3 is associated with an increased risk for disease relapse.
authors.affiliation: Division of Oncology, Children's Hospital of Philadelphia, Pennsylvania 19104-4138, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Maris
authors.forename: C
authors.initials: C
authors.lastname: Guo
authors.forename: D
authors.initials: D
authors.lastname: Blake
authors.forename: P S
authors.initials: PS
authors.lastname: White
authors.forename: M D
authors.initials: MD
authors.lastname: Hogarty
authors.forename: P M
authors.initials: PM
authors.lastname: Thompson
authors.forename: V
authors.initials: V
authors.lastname: Rajalingam
authors.forename: R
authors.initials: R
authors.lastname: Gerbing
authors.forename: D O
authors.initials: DO
authors.lastname: Stram
authors.forename: K K
authors.initials: KK
authors.lastname: Matthay
authors.forename: R C
authors.initials: RC
authors.lastname: Seeger
authors.forename: G M
authors.initials: GM
authors.lastname: Brodeur
mesh_terms: D000483:Alleles; D002648:Child; D002675:Child, Preschool; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics / Q000648:ultrastructure*; D018572:Disease-Free Survival; D016147:Genes, Tumor Suppressor; D006801:Humans; D007223:Infant; D015993:Life Tables; D019656:Loss of Heterozygosity; D009447:Neuroblastoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D016133:Polymerase Chain Reaction; D016016:Proportional Hazards Models; D012306:Risk; D016019:Survival Analysis